The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
Open Access
- 3 June 2021
- Vol. 9 (6), 598
- https://doi.org/10.3390/vaccines9060598
Abstract
Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy after the pandemic resolves. Methods: A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94. Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of clinical infections (−682,000), hospitalizations (−5800) and deaths (−740) in the UK. The base case incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50- to 64-year-olds with QIVc became cost-saving. Conclusion: Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.Funding Information
- Seqirus USA Inc. (Not applicable)
This publication has 28 references indexed in Scilit:
- Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019–2020 SeasonClinical Infectious Diseases, 2020
- Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017-2018Clinical Infectious Diseases, 2020
- Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018–2019The Journal of Infectious Diseases, 2020
- Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017-2018The Journal of Infectious Diseases, 2019
- Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017–2018Vaccine, 2019
- Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017–2018 influenza seasonVaccine, 2019
- Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderlyVaccine, 2019
- Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness studyBMC Medicine, 2015
- Health and economic impact of the seasonal influenza vaccination programme in EnglandVaccine, 2012
- Internet-based surveillance of Influenza-like-illness in the UK during the 2009 H1N1 influenza pandemicBMC Public Health, 2010